Etiology of Multiple Myeloma: A Case-Control Study
The overall objective of this project is to identify risk factors associated with the development of multiple myeloma (MM) by integrating epidemiologic, clinical and molecular information. We plan to invite MDACC patients with MM, as well as controls, to participate in this investigative case-control study. Controls will be selected from friends and spouses who accompany patients to the various MDACC clinics and will be matched to the cases on age (±5 years), gender, and ethnicity. We will obtain demographic, risk factor and clinical information along with a blood and buccal sample from all cases and controls. This study could have implications for prevention and subsequent reduction in the incidence of multiple myeloma. Collecting blood and buccal samples will allow us to study the role genetic susceptibility plays in MM risk. The specific aims are:
- To enroll and obtain, through self-administered questionnaires, risk factor information on all study participants to develop detailed demographic, epidemiologic, and behavioral profiles. This study will accrue 250 MM patients from MDACC and 250 healthy controls selected from friends and spouses who accompany patients to the MDACC clinics. Blood (25 ml) and buccal samples will be collected from all participants.
- To identify risk factors associated with MM by integrating epidemiological, clinical and molecular information using a case-control approach.
- To evaluate constitutional markers of genetic susceptibility as predictors of MM risk. Gene-environment interactions will be explored.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Etiology of Multiple Myeloma: A Case-Control Study|
- The goal of this epidemiological research study is to identify biological and lifestyle factors that may be associated with the development of Multiple Myeloma (MM). [ Time Frame: 2 Years ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||July 2006|
|Estimated Primary Completion Date:||July 2018 (Final data collection date for primary outcome measure)|
Patients diagnosed with Multiple Myeloma and healthy controls.
Questionnaire taking 30-40 minutes to complete.
Other Name: Survey
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00505999
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Michelle Hildebrandt, PhD||M.D. Anderson Cancer Center|